Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Publication year range
1.
Sci Rep ; 13(1): 7306, 2023 05 05.
Article in English | MEDLINE | ID: mdl-37147348

ABSTRACT

The rapid spread of the SARS-CoV-2 Variant of Concern (VOC) Gamma in Amazonas during early 2021 fueled a second large COVID-19 epidemic wave and raised concern about the potential role of reinfections. Very few cases of reinfection associated with the VOC Gamma have been reported to date, and their potential impact on clinical, immunological, and virological parameters remains largely unexplored. Here we describe 25 cases of SARS-CoV-2 reinfection in Brazil. SARS-CoV-2 genomic analysis confirmed that individuals were primo-infected with distinct viral lineages between March and December 2020 (B.1.1, B.1.1.28, B.1.1.33, B.1.195, and P.2) and reinfected with the VOC Gamma between 3 to 12 months after primo-infection. We found a similar mean cycle threshold (Ct) value and limited intra-host viral diversity in both primo-infection and reinfection samples. Sera of 14 patients tested 10-75 days after reinfection displayed detectable neutralizing antibodies (NAb) titers against SARS-CoV-2 variants that circulated before (B.1.*), during (Gamma), and after (Delta and Omicron) the second epidemic wave in Brazil. All individuals had milder or no symptoms after reinfection, and none required hospitalization. These findings demonstrate that individuals reinfected with the VOC Gamma may display relatively high RNA viral loads at the upper respiratory tract after reinfection, thus contributing to onward viral transmissions. Despite this, our study points to a low overall risk of severe Gamma reinfections, supporting that the abrupt increase in hospital admissions and deaths observed in Amazonas and other Brazilian states during the Gamma wave was mostly driven by primary infections. Our findings also indicate that most individuals analyzed developed a high anti-SARS-CoV-2 NAb response after reinfection that may provide some protection against reinfection or disease by different SARS-CoV-2 variants.


Subject(s)
COVID-19 , SARS-CoV-2 , Humans , SARS-CoV-2/genetics , Brazil/epidemiology , COVID-19/epidemiology , Antibody Diversity , Gamma Rays , Reinfection , Patient Acuity
2.
iScience ; 25(4): 104156, 2022 Apr 15.
Article in English | MEDLINE | ID: mdl-35368908

ABSTRACT

The COVID-19 epidemic in Brazil experienced two major lineage replacements until mid-2021. The first was driven by lineage P.2, in late 2020, and the second by lineage Gamma, in early 2021. To understand how these SARS-CoV-2 lineages spread in Brazil, we analyzed 11,724 genomes collected throughout the country between September 2020 and April 2021. Our findings indicate that lineage P.2 probably emerged in July 2020 in the Rio de Janeiro state and Gamma in November 2020 in the Amazonas state. Both states were the main hubs of viral disseminations to other Brazilian locations. We estimate that Gamma was 1.56-3.06 times more transmissible than P.2 in Rio de Janeiro and that the median effective reproductive number (Re) of Gamma varied according to the geographic context (Re = 1.59-3.55). In summary, our findings support that lineage Gamma was more transmissible and spread faster than P.2 in Brazil.

3.
Microbiol Spectr ; 10(1): e0236621, 2022 02 23.
Article in English | MEDLINE | ID: mdl-35196783

ABSTRACT

The Amazonas was one of the most heavily affected Brazilian states by the COVID-19 epidemic. Despite a large number of infected people, particularly during the second wave associated with the spread of the Variant of Concern (VOC) Gamma (lineage P.1), SARS-CoV-2 continues to circulate in the Amazonas. To understand how SARS-CoV-2 persisted in a human population with a high immunity barrier, we generated 1,188 SARS-CoV-2 whole-genome sequences from individuals diagnosed in the Amazonas state from 1st January to 6th July 2021, of which 38 were vaccine breakthrough infections. Our study reveals a sharp increase in the relative prevalence of Gamma plus (P.1+) variants, designated Pango Lineages P.1.3 to P.1.6, harboring two types of additional Spike changes: deletions in the N-terminal (NTD) domain (particularly Δ144 or Δ141-144) associated with resistance to anti-NTD neutralizing antibodies or mutations at the S1/S2 junction (N679K or P681H) that probably enhance the binding affinity to the furin cleavage site, as suggested by our molecular dynamics simulations. As lineages P.1.4 (S:N679K) and P.1.6 (S:P681H) expanded (Re > 1) from March to July 2021, the lineage P.1 declined (Re < 1) and the median Ct value of SARS-CoV-2 positive cases in Amazonas significantly decreases. Still, we did not find an increased incidence of P.1+ variants among breakthrough cases of fully vaccinated patients (71%) in comparison to unvaccinated individuals (93%). This evidence supports that the ongoing endemic transmission of SARS-CoV-2 in the Amazonas is driven by the spread of new local Gamma/P.1 sublineages that are more transmissible, although not more efficient to evade vaccine-elicited immunity than the parental VOC. Finally, as SARS-CoV-2 continues to spread in human populations with a declining density of susceptible hosts, the risk of selecting more infectious variants or antibody evasion mutations is expected to increase. IMPORTANCE The continuous evolution of SARS-CoV-2 is an expected phenomenon that will continue to happen due to the high number of cases worldwide. The present study analyzed how a Variant of Concern (VOC) could still circulate in a population hardly affected by two COVID-19 waves and with vaccination in progress. Our results showed that the answer behind that was a new generation of Gamma-like viruses, which emerged locally carrying mutations that made it more transmissible and more capable of spreading, partially evading prior immunity triggered by natural infections or vaccines. With thousands of new cases daily, the current pandemics scenario suggests that SARS-CoV-2 will continue to evolve and efforts to reduce the number of infected subjects, including global equitable access to COVID-19 vaccines, are mandatory. Thus, until the end of pandemics, the SARS-CoV-2 genomic surveillance will be an essential tool to better understand the drivers of the viral evolutionary process.


Subject(s)
COVID-19/enzymology , Furin/metabolism , SARS-CoV-2/genetics , Spike Glycoprotein, Coronavirus/chemistry , Spike Glycoprotein, Coronavirus/genetics , Amino Acid Motifs , Brazil/epidemiology , COVID-19/epidemiology , COVID-19/transmission , COVID-19/virology , COVID-19 Vaccines/administration & dosage , Furin/genetics , Genomics , Humans , Mutation , Phylogeny , SARS-CoV-2/classification , SARS-CoV-2/isolation & purification , SARS-CoV-2/metabolism , Spike Glycoprotein, Coronavirus/metabolism
5.
Arq. neuropsiquiatr ; 54(2): 318-23, jun. 1996. ilus
Article in Portuguese | LILACS | ID: lil-172059

ABSTRACT

Linfomas näo Hodgkin de alto grau sao comumente relatados em pacientes com a síndrome da imunodeficiência adquirida (AIDS). Comprometendo com grande frequência o sistema nervoso central, particularmente as leptomeninges e os hemisférios cerebrais. O acometimento epidural é pouco frequente, variando de 3,5 por cento a 8,3 por cento de acordo com os registros da literatura. Os autores relatam o caso de um paciente de 27 anos de idade com AIDS, cuja manifestaçao clínica inicial da doença linfomatosa disseminada foi a mielite transversa associada à mielopatia vacuolar. Destaca-se a importância do diagnóstico diferencial precoce das mielopatias na AIDS, em virtude da alta malignidade da neoplasia e da evoluçao extremamente rápida nesses pacientes.


Subject(s)
Humans , Male , Adult , Spinal Cord Diseases/etiology , Lymphoma, Non-Hodgkin/etiology , Lymphoma, AIDS-Related/pathology , Myelitis, Transverse/etiology , Acquired Immunodeficiency Syndrome/complications , Vacuoles/pathology , Diagnosis, Differential , Spinal Cord Diseases/diagnosis , Spinal Cord Diseases/pathology , Lymphoma, Non-Hodgkin/complications , Lymphoma, Non-Hodgkin/pathology , Myelitis, Transverse/diagnosis , Myelitis, Transverse/pathology , Acquired Immunodeficiency Syndrome/pathology
6.
Rev. Cent. Ciênc. Bioméd. Univ. Fed. Uberlândia ; 8(1): 45-52, dez. 1992. ilus, tab
Article in Portuguese | LILACS | ID: lil-141110

ABSTRACT

O virus da hepatite C(HCV), tem sido identificado como sendo o principal agente causador das hepatites nao-A, nao-B. A deteccao dos anticorpos IgG anti-HCV e realizada pelo ELISA convencional (ELISAc) e a sua avidez pode ser determinada pelo ELISA modificado (ELISAm).Foram estudados 34 pacientes hemodialisados (M:19; F:15), com media de idade de 45+- 2,3 anos, recebendo regularmente hemotransfusoes, quanto a presenca de anticorpos IgG anti-HCV (ELISAc) bem como sua avidez (ELISAm). A prevalencia para anti-HCV foi de 23,5 por cento (8/34), sendo que 62,5 por cento (5/8) eram do sexo feminino, verificando-se maior prevalencia diretamente relacionada com o tempo de hemodialise e o numero de transfusoes sanguineas. Todas as amostras soropositivas apresentaram indice de avidez superior a 80 por cento caracterizando quadro de infeccao cronica. Conclui-se que pacientes hemodialisados constituem grupo de risco potencial para a infeccao pelo HCV, sendo necessario medidas de isolamento para prevenir a disseminacao desta infeccao


Subject(s)
Humans , Renal Dialysis , Hepatitis C/epidemiology , Brazil/epidemiology , Prevalence
SELECTION OF CITATIONS
SEARCH DETAIL
...